FASN and metabolic dysfunction-associated steatotic liver disease: Moreover, Gao et al. have shown that MPC1 regulates the Kla of fatty acid synthase, and specifically, the Kla at the K673 site inhibits fatty acid synthase activity, leading to reduced liver lipid accumulation, which may offer insights into developing treatments for non-alcoholic fatty liver disease [80].